Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06578546
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-04-27
Brief Title:
Chemotherapy-free Regimen of Venetoclax Azacitidine Plus Orebatinib VAO Regimen for Newly Diagnosed phALL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-arm Open Label Multicenter Clinical Study to Evaluate the Safety and Efficacy of VAO Regimen in Patients With Newly Diagnosed Ph-positive Acute Lymphoblastic Leukemia
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Venetoclax Azacitidine Plus Orebatinib in newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia
Detailed Description:
This is a phase Ⅱ single-arm open Label multicenter clinical study in newly diagnosed Ph-positive acute lymphoblastic leukemia patients The patients will receive venetoclax azacitidine and orebatinib regimen in the induction treatment The patients who respond to induction treatment will undergo consolidation treatment and an optional allogeneic hematopoietic stem cell transplantation and post-transplantation maintenance treatment with induction therapy according to patients wishes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None